MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells

Current treatment for patients with metastatic melanoma include molecular-targeted therapies and immune checkpoint inhibitors. However, a subset of melanomas are difficult-to-treat. These melanomas include those without the genetic markers for targeted therapy, non-responsive to immunotherapy, and t...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cell Death Dis
Main Authors: Mukherjee, Nabanita, Skees, Jenette, Todd, Kaleb J., West, Drake A., Lambert, Karoline A., Robinson, William A., Amato, Carol M., Couts, Kasey L., Van Gullick, Robert, MacBeth, Morgan, Nassar, Kelsey, Tan, Aik-Choon, Zhai, Zili, Fujita, Mayumi, Bagby, Stacey M., Dart, Chiara R., Lambert, James R., Norris, David A., Shellman, Yiqun G.
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group UK 2020
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7280535/
https://ncbi.nlm.nih.gov/pubmed/32513939
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41419-020-2646-2
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares